Substance / Medication

Etretinate

Overview

Active Ingredient
etretinate
RxNorm CUI
4182

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

145 trials linked to this intervention

145
Total Trials
25
Recruiting
61
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Completed suicide in patients with skin disease: A systematic review and meta-analysis.
Hrvatin Stancic B, Henning M A S, Eriksen N et al. · J Eur Acad Dermatol Venereol · 2026
PMID: 40091608Meta-AnalysisFull text (PMC)
Systematic Review of Accelerated Epigenetic Aging in Chronic Inflammatory Dermatology Conditions.
Dulai Ajay S, Joshi Aditya, Min Mildred et al. · Int J Dermatol · 2026
PMID: 40940698Meta-Analysis
Ocular Comorbidities of Psoriasis: A Systematic Review and Meta-analysis of Observational Studies.
Wang Ching-Ya, Lin Tzu-Yi, Wang Tzu-Yu et al. · Am J Ophthalmol · 2026
PMID: 40975155Meta-Analysis
Obesity as a Risk Factor for Autoimmune Diseases: A Systematic Review and Meta-Analysis.
Spatocco Ilaria, Mele Giorgia, De Rosa Giusy et al. · Obesity (Silver Spring) · 2026
PMID: 41186974Meta-AnalysisFull text (PMC)
The Relative Effects of Monotherapies for Psoriatic Nails: A Network Meta-Analysis Study.
Gupta Aditya K, Bamimore Mary A, Wang Tong et al. · J Cosmet Dermatol · 2026
PMID: 41502049Meta-AnalysisFull text (PMC)
The Vitamin A derivative etretinate improves skin sclerosis in patients with systemic sclerosis.
Ikeda Takaharu, Uede Koji, Hashizume Hideo et al. · J Dermatol Sci · 2004
PMID: 14757285Trial
Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis.
Qu Z X, Pliskin N, Jensen M W et al. · Arch Neurol · 2001
PMID: 11176940Trial
In vivo and in vitro influence of etretinate on erythrocyte membrane fluidity.
Górnicki A, Gutsze A · Eur J Pharmacol · 2001
PMID: 11448476Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Etretinate (substance)
SNOMED CT
386937001
UMLS CUI
C0015137
RxNorm CUI
4182

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
145
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.